致癌性RAF：时间简史 - Suppr

Suppr

超能文献

Oncogenic RAF: a brief history of time.

作者信息

Solit David, Rosen Neal

机构信息

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

出版信息

Pigment Cell Melanoma Res. 2010 Dec;23(6):760-2. doi: 10.1111/j.1755-148X.2010.00779.x.

DOI:10.1111/j.1755-148X.2010.00779.x

PMID:20973931

Abstract

摘要

相似文献

Oncogenic RAF: a brief history of time.

Pigment Cell Melanoma Res. 2010 Dec;23(6):760-2. doi: 10.1111/j.1755-148X.2010.00779.x.

BRAF signaling and targeted therapies in melanoma.

Hematol Oncol Clin North Am. 2009 Jun;23(3):529-45, ix. doi: 10.1016/j.hoc.2009.04.001.

Drug discovery: How melanomas bypass new therapy.

Nature. 2010 Dec 16;468(7326):902-3. doi: 10.1038/468902a.

Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.

J Clin Oncol. 2013 Jul 1;31(19):e324-6. doi: 10.1200/JCO.2012.46.1061. Epub 2013 May 28.

Resistance to BRAF inhibition in melanomas.

N Engl J Med. 2011 Feb 24;364(8):772-4. doi: 10.1056/NEJMcibr1013704.

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Nature. 2010 Sep 30;467(7315):596-9. doi: 10.1038/nature09454.

The genesis of Zelboraf: targeting mutant B-Raf in melanoma.

J Cell Biol. 2012 Oct 1;199(1):15-9. doi: 10.1083/jcb.201205167.

Effectively targeting BRAF in melanoma: a formidable challenge.

Pigment Cell Melanoma Res. 2008 Aug;21(4):410-1. doi: 10.1111/j.1755-148X.2008.00485.x.

B-Raf associates with and activates the NHE1 isoform of the Na+/H+ exchanger.

J Biol Chem. 2011 Apr 15;286(15):13096-105. doi: 10.1074/jbc.M110.165134. Epub 2011 Feb 23.

Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.

Mol Cancer Ther. 2010 Jul;9(7):2090-101. doi: 10.1158/1535-7163.MCT-10-0073. Epub 2010 Jun 22.

引用本文的文献

BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers.

Cancers (Basel). 2023 Aug 8;15(16):4026. doi: 10.3390/cancers15164026.

Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology.

Biomed Hub. 2020 Sep 14;5(3):182-223. doi: 10.1159/000511209. eCollection 2020 Sep-Dec.

Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAF-Specific Inhibitor).

Cancers (Basel). 2018 May 24;10(6):157. doi: 10.3390/cancers10060157.

Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma.

BMC Cancer. 2014 Aug 29;14:630. doi: 10.1186/1471-2407-14-630.

Markers of resistance to anti-EGFR therapy in colorectal cancer.

J Gastrointest Oncol. 2013 Sep;4(3):308-18. doi: 10.3978/j.issn.2078-6891.2013.029.

Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.

PLoS One. 2012;7(1):e29336. doi: 10.1371/journal.pone.0029336. Epub 2012 Jan 3.

Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-κB pathways.

Pigment Cell Melanoma Res. 2011 Aug;24(4):703-13. doi: 10.1111/j.1755-148X.2011.00867.x. Epub 2011 Jun 6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Oncogenic RAF: a brief history of time.

Pigment Cell Melanoma Res. 2010 Dec;23(6):760-2. doi: 10.1111/j.1755-148X.2010.00779.x.

BRAF signaling and targeted therapies in melanoma.

Hematol Oncol Clin North Am. 2009 Jun;23(3):529-45, ix. doi: 10.1016/j.hoc.2009.04.001.

Drug discovery: How melanomas bypass new therapy.

Nature. 2010 Dec 16;468(7326):902-3. doi: 10.1038/468902a.

Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.

J Clin Oncol. 2013 Jul 1;31(19):e324-6. doi: 10.1200/JCO.2012.46.1061. Epub 2013 May 28.

Resistance to BRAF inhibition in melanomas.

N Engl J Med. 2011 Feb 24;364(8):772-4. doi: 10.1056/NEJMcibr1013704.

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Nature. 2010 Sep 30;467(7315):596-9. doi: 10.1038/nature09454.

The genesis of Zelboraf: targeting mutant B-Raf in melanoma.

J Cell Biol. 2012 Oct 1;199(1):15-9. doi: 10.1083/jcb.201205167.

Effectively targeting BRAF in melanoma: a formidable challenge.

Pigment Cell Melanoma Res. 2008 Aug;21(4):410-1. doi: 10.1111/j.1755-148X.2008.00485.x.

B-Raf associates with and activates the NHE1 isoform of the Na+/H+ exchanger.

J Biol Chem. 2011 Apr 15;286(15):13096-105. doi: 10.1074/jbc.M110.165134. Epub 2011 Feb 23.

Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.

Mol Cancer Ther. 2010 Jul;9(7):2090-101. doi: 10.1158/1535-7163.MCT-10-0073. Epub 2010 Jun 22.

引用本文的文献

BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers.

Cancers (Basel). 2023 Aug 8;15(16):4026. doi: 10.3390/cancers15164026.

Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology.

Biomed Hub. 2020 Sep 14;5(3):182-223. doi: 10.1159/000511209. eCollection 2020 Sep-Dec.

Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAF-Specific Inhibitor).

Cancers (Basel). 2018 May 24;10(6):157. doi: 10.3390/cancers10060157.

Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma.

BMC Cancer. 2014 Aug 29;14:630. doi: 10.1186/1471-2407-14-630.

Markers of resistance to anti-EGFR therapy in colorectal cancer.

J Gastrointest Oncol. 2013 Sep;4(3):308-18. doi: 10.3978/j.issn.2078-6891.2013.029.

Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.

PLoS One. 2012;7(1):e29336. doi: 10.1371/journal.pone.0029336. Epub 2012 Jan 3.

Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-κB pathways.

Pigment Cell Melanoma Res. 2011 Aug;24(4):703-13. doi: 10.1111/j.1755-148X.2011.00867.x. Epub 2011 Jun 6.